Abstract |
The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very- low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-alpha agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1+/-12.7 vs. 202.2+/-16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58+/-26.2 vs. 107.47+/-25.0 pg/ml, p<0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.
|
Authors | M Mráz, Z Lacinová, P Kaválková, D Haluzíková, P Trachta, J Drápalová, V Hanušová, M Haluzík |
Journal | Physiological research
(Physiol Res)
Vol. 60
Issue 4
Pg. 627-36
( 2011)
ISSN: 1802-9973 [Electronic] Czech Republic |
PMID | 21574752
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Blood Glucose
- FGF19 protein, human
- PPAR alpha
- Fibroblast Growth Factors
- Fenofibrate
|
Topics |
- Acute Disease
- Adult
- Biomarkers
(blood)
- Blood Glucose
(metabolism)
- Caloric Restriction
(methods)
- Diabetes Mellitus, Type 2
(blood, therapy)
- Female
- Fenofibrate
(pharmacology, therapeutic use)
- Fibroblast Growth Factors
(blood)
- Humans
- Hyperinsulinism
(blood, therapy)
- Insulin Resistance
- Middle Aged
- Obesity
(blood)
- PPAR alpha
(agonists, physiology)
- Treatment Outcome
|